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A
Polymorphisms of cyclo-oxygenases and
5-lipo-oxygenase-activating protein are
associated with chronic spontaneous urticaria
and urinary leukotriene E4
Background. The mechanisms of chronic spontaneous urticaria (CSU)
continue to be unknown.
Objects. Our working hypothesis is that polymorphisms of cyclo-
oxygenases and 5-lipo-oxygenase-activating protein may be involved
in the pathways leading to CSU.
Methods. We examined five candidate polymorphisms of cyclo-
oxygenases 1 and 2 and of 5-lipo-oxygenase-activating protein in 109
controls and in 94 CSU patients from Northern Italy. We also examined
the levels of urinary leukotriene E4 (LTE4) before and after challenge
with ASA.
Results. A multiple regression model was found to show that COX-2
5′UTR T/G, COX-2 Exon 10 T/C, and FLAP -336 G/A polymorphisms
were significantly associated with CSU, with the minor allele more repre-
sented in CSU group. Similar results were obtained as regards the specific
association with ASA-tolerated CSU and ASA-exacerbated CSU. Eva-
luating a polygenic model, reflecting the sum of the concomitant alleles
associated with CSU (i.e. COX-2 5′UTR G allele, COX-2 Exon 10 C
allele, and FLAP -336 G/A allele), the proportion of CSU patients
increased progressively with the increasing number of unfavourable
alleles. Finally, in a linear regression model after adjustment for dis-
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cease status COX-1 22 T carriership remained a significant predictor of
post-challenge high urinary LTE4 levels.
Conclusions. Our results support the hypothesis that polymorphisms
of cyclo-oxygenases and 5-lipo-oxygenase-activating protein may be
associated with CSU.
Key words: chronic spontaneous urticaria, hypersensivity to aspirin,
cyclo-oxygenases, 5-lipo-oxygenase-activating protein, urinaryrticle accepted on 10/13/2010 leukotriene E4
rachidonic acid, released from the mammalian
cell membrane, may be metabolized through two
main pathways: the cyclooxygenase (COX) path-
ay to yielding prostanoids or the 5-lipo-oxygenase (5-LO)
athway to form the unstable intermediary LTA4, which,
epending on distal enzymes differentially expressed in
eukocytes, is metabolized to either LTB4 or the cysteinyl
eukotrienes (CysLTs). These mediators are involved in
variety of clinically important areas such as inflamma-
ion, fever, thrombosis, allergic and immune responses,
nd cancer. Acetylsalicylic acid (ASA) causes a shift in
he arachidonic acid metabolism away from the cyclooxy-
enase (COX) pathway toward the lipo-oxygenase (LO)
athways [1]. ASA-induced asthma (AIA) is thought toJD, vol. 21, n◦ 1, January-February 2011
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and 5-lipo-oxygenase-activating protein are associated with chronic spontaneous urticaria and
e caused by a shift in the arachidonic acid metabolism
athaway. The identification of genetic factors that confer
usceptibility to the development of acetylsalicylic acid
ASA) exacerbated chronic spontaneous urticaria (AeCSU)
ould contribute to the understanding of the disease [2]. Incontrast with AIA, progress in understanding ASA-induced
urticaria has been slow. Clinicians are well aware that up to
20% to 40% of patients with chronic spontaneous urticaria
(CSU) develop an increase in wheals and swelling after
ASA. It was reported that, in some of them, not only
ASA but also several other nonsteroidal anti-inflammatory
drugs (NSAIDs) inhibit COX triggered skin eruptions [3].
Recent studies on eicosanoid metabolism showed that cox-
ibs, selective COX-2 inhibitors, did not precipitate wheals
and swelling in patients with chronic urticaria who were
sensitive to aspirin [4-6]. It was also shown that AeCSU
is associated with overproduction of cysteinyl-leukotrienes
(cys-LTs), as reflected by increased urinary excretion of
leukotriene E4 (LTE4) [7, 8]. However, when we compared47
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urinary LTE4 levels in the same subjects, we found no dif-
ference at baseline between the groups before challenge
with ASA; we found an increase in leukotriene levels after
challenge but only in patients with CSU [7]. These results
could explain the different clinical responses to therapy with
4Table 1. Clinical characteristic of the study population divided in subgroups according to clinical diagnosis (i.e. normal controls
(NC) and patients with chronic spontaneous urticaria (CSU). The latter group was further divided in 2 subgroups: ASA tolerated
chronic idiopathic urticaria (AtCSU) and ASA exacerbated chronic urticaria (AeCSU)).
NC
(n= 109)
CSU
(n = 94)
AtCSU
(n = 31)
AeCSU
(n = 63)
Age
(years)
36.5 ± 13.8 39.2 ± 13.2 39.6 ± 13.3 39.0 ± 13.3
Males
n (%)
33 (30.3) 24 (25.5) 4 (12.9)* 20 (31.7)
Positive ASA challenge
n (%)
0 (0) 63 (67.0) 0 (0) 63 (100)
LTE4 levels before challenge with ASA 15.7 ± 1.08 15.5 ± 2.05 16.0 ± 1.1
*
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HLTE4 levels after challenge with ASA 15.2 ± 2.1
P=0.049 by 2-test versus AeCSU
P< 0.001 by t-test versus both NC and AtCSU
eukotriene receptor antagonist (LT-RAs) in patients with
SU with or without well-defined triggers, as we observed
n two placebo-controlled trials with antileukotriene [9, 10].
he aim of this study was to investigate in a case-control
etting the potential association of 5 candidate polymor-
hisms of genes of cyclo-oxygenases 1 and 2 and of
-lipo-oxygenase-activating protein (COX-1 22 C/T, COX-
-162C/G, COX-2 5′UTR T/G, COX-2 Exon 10 T/C,
nd FLAP -336 G/A) with CSU, as well as with urinary
TE4 levels, both basal and after challenge with ASA.
atients with CSU were further divided into ASA-tolerated
SU (AtCSU) and AeCSU subgroups and analyzed
eparately.
ethods
atients
inety-four patients with CSU, 24 male and 70 female;
ean age: 39.2 yrs (range 18-71 years), were randomly
elected by chart review from outpatients of the Diparti-
ento di Medicina Clinica e Sperimentale of Verona (Italy).8
ll the patients had been previously submitted to oral chal-
enge double-blind placebo-controlled (DBPC) for the ASA
sing three capsules of placebo (talc) and 10, 10, 20 mg
raded doses in brackets. The diagnosis of ASA exac-
rbation (AeCSU) or ASA-tolerated CSU (AtCSU) was
bbreviations:
SU chronic spontaneous urticaria
SA aspirin
SAID nonsteroidal anti-inflammatory drugs
HCU aspirin-hypersensitivity chronic urticaria
AHCU chronic urticaria with negative response to aspirin
ys-LT cysteinyl-leukotrienes
TE4 leukotriene E4
OXs cyclo-oxygenases
LAP 5-lipo-oxygenase-activating protein
NP single nucleotide polymorphisms
TRA LT receptor antagonist
C normal healthy controls
CR polymerase chain reaction
WE Hardy-Weinberg equilibrium14.9 ± 2.1 69.5 ± 10.4§
based on a positive response or a negative response to ASA
challenge, respectively [7]. Of these, 63 were AeCSU (67%)
and 31 were AtCSU, respectively.
A total of 109 normal healthy controls (NC) (33 males and
76 females; mean age: 36.5 yrs (range 18-71 years)) were
randomly selected from the pool of healthy volunteers who
come to Dipartimento di Medicina Clinica e Sperimentale
of Verona for a routine medical examination or who work
at the clinic. NC had no history of urticaria or asthmatic or
rhinitic symptoms or aspirin hyper-responsiveness. All the
NC performed an oral challenge DBPC with ASA which
resulted negative in all subjects. The demographic charac-
teristics of patients and the NC are reported in table 1. We
used R.2.7.1 (http://www.r-project.org/) for random selec-
tion of participants. All the participants were of the same
ethnic background (Caucasians). In all subjects, renal func-
tion (serum and urinary creatinine, clearance of creatinine
and bun) was normal.
Study protocol
Based on the results of previous challenges to ASA (see
above) the AeCSU were re-challenged with a single dose of
ASA, precisely with that dose which had induced urticaria
on previous challenge with ASA, and with placebo. AtCSU
patients and NC were re-challenged with 20 mg of ASA
and placebo.
The AeCSU patients were re-challenged twice, on different
days, with ASA which have induced urticaria to previous
challenge with ASA and with placebo. The AtCSU patients
and NC were re-challenged twice with 20 mg of ASA and
with placebo. None of the patients showed significant cuta-
neous symptoms at the time of testing. Antihistamines were
interrupted at least 8 days before the challenges, and no
drugs were used within 48 h of testing. No patient had taken
oral corticosteroids.
All the AeCSU patients presented the onset of urticaria
(weal and erythema) after 30-45 min. after the ingestion
of ASA. None of the AtCSU and NC presented urticaria
with 20 mg of ASA. None of the subjects studied presented
urticaria after placebo.EJD, vol. 21, n◦ 1, January-February 2011
LTE4 determination in urine
Urinary LTE4 was measured before and after ASA chal-
lenge. Measurements were made at same time, in duplicate,
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*nd expressed as nanograms per milligram of creatinine.
TE4 determination in urine was performed exactly as
escribed by Di Lorenzo et al. [7-11].
olecular methods
he method used to extract the DNA was salting-out,
ollowing the standard protocol [12]. The DNA samples
ere amplified for -336 G/A polymorphism of FLAP gene
y a polymerase chain reaction (PCR). Concerning the
2 C/T of COX-1 gene and -162 C/G, 5′UTR T/G, and
xon10 T/C polymorphisms of COX-2 gene, DNA sam-
les were analyzed by PCR-SSP, using a PCR thermal
equencer (MyCycler Biorad, Milan, Italy). The products
ere obtained after amplification in a 20 L volume con-
aining 20 ng of genomic DNA template, 1 U of Taq
NA polymerase, 200 M dNTP, 1X buffer containing
10 mmol/L Tris-HCl pH 8.3, 50 mmol/L KCl), 1.3 mmol/L
gCl2, and 0.2 pmol/L of each amplification primer.
tatistical analysisJD, vol. 21, n◦ 1, January-February 2011
alculations were performed with the SPSS 17.0 statistical
ackage (SPSS Inc., Chicago, IL). Distributions of continu-
us variables in groups were expressed as means ± standard
eviation. Quantitative data were assessed using the
tudent’s t-test or by ANOVA. Qualitative data were
able 2. Genotypic distributions of COX-1, COX-2, and FLAP p
ccording to clinical diagnosis (i.e. normal controls (NC) and pa
roup was further divided in 2 subgroups: ASA tolerated chronic s
pontaneous urticaria (AeCSU).
Gene SNP Genotype NC
(n = 109)
CSU
(n = 94)
NC vs N
vs CSU
P *
COX-1 22 CC 100 (91.7) 73 (77.7)
C/T CT 8 (7.4) 15 (16.0) 0.012
n (%) TT 1 (0.9) 6 (6.3)
T carrier 9 (8.3) 21 (22.3) 0.005
COX-2 -162 CC 39 (35.8) 29 (30.9)
C/G CG 57 (52.3) 52 (55.3) 0.743
n (%) GG 13 (11.9) 13 (13.8)
G carrier 70 (64.2) 65 (69.1) 0.458
5′UTR TT 103 (94.5) 67 (71.3)
T/G TG 6 (5.5) 16 (17.0) <0.001
n (%) GG 0 (0) 11 (11.7)
G carrier 6 (5.5) 27 (28.7) <0.001
Exon 10 TT 98 (89.9) 72 (76.6)
T/C TC 10 (9.2) 20 (21.3) 0.037
n (%) CC 1 (0.9) 2 (2.1)
C carrier 11 (10.1) 22 (23.4) 0.010
FLAP -336 GG 99 (90.8) 60 (63.8)
G/A GA 10 (9.2) 29 (30.9) <0.001
n (%) AA 0 (0) 5 (5.3)
A carrier 10 (9.2) 34 (36.2) <0.001
by 2-testanalyzed with the 2-test. Considering the low frequency
of minor allele homozygotes, most analyses were per-
formed comparing the carriers of the minor allele (heterozy-
gotes + homozygotes) with major allele homozygotes.
A value of P< 0.05 was considered statistically significant.
Hardy-Weinberg equilibrium (HWE) was tested for each
genotype within the control group by means of 2-test. To
assess the extent to which gene polymorphisms were associ-
ated with CSU (as well as with AtCSU and with AeCSU),
odds ratios with 95% CIs were estimated by a sex- and
age-adjusted logistic regression analysis. A logistic regres-
sion model was also used to analyze potential interactions
among gene polymorphisms in predicting CSU risk. Then
we focused on a polygenic additive model. On this basis,
we attributed to each patient a “score”, reflecting the sum
of the “unfavourable” CSU-associated alleles, theoretically
ranging from 0 (no risk allele present) to 6 (all the risk alle-
les present). The association between this score and CSU
was evaluated by 2 for linear trend analysis.
Finally, a linear regression analysis adjusted for sex, age,
and disease status was performed to assess which polymor-
phisms were independent predictors of urinary LTE4 levels
variability.49
The study was approved by Ethical Committee of Verona
and written informed consent to the study was obtained
from each patient. The study was performed following the
Helsinki Declaration of 1975, as amended in 1983.
olymorphisms in the study population divided in subgroups
tients with chronic spontaneous urticaria (CSU). The latter
pontaneous urticaria (AtCSU) and ASA exacerbated chronic
C AtCSU
(n = 31)
NC vs
AtCSU
P *
AeCSU
(n = 63)
NC vs
AeCSU
P *
AeCSU vs
AtCSU
P *
24 (77.4) 49 (77.8)
5 (16.1) 0.049 10 (15.9) 0.021 0.999
2 (6.5) 4 (6.3)
7 (22.6) 0.027 14 (22.2) 0.010 0.969
10 (32.3) 19 (30.2)
16 (51.6) 0.811 36 (57.1) 0.753 0.852
5 (16.1) 8 (12.7)
21 (67.7) 0.717 44 (69.8) 0.452 0.836
23 (74.2) 44 (69.8)
4 (12.9) <0.001 12 (19.1) <0.001 0.751
4 (12.9) 7 (11.1)
8 (25.8) 0.001 19 (30.2) <0.001 0.661
21 (67.7) 51 (81.0)
9 (29.0) 0.010 11 (17.5) 0.250 0.360
1 (3.3) 1 (1.5)
10 (32.3) 0.002 12 (19.0) 0.096 0.155
17 (54.8) 43 (68.3)
10 (32.3) <0.001 19 (30.2) 0.001 0.060
4 (12.9) 1 (1.5)
14 (45.2) <0.001 20 (31.7) <0.001 0.203
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Figure 1. Odd Ratios (ORs) for chronic spontaneous urticaria
(CSU) (A), ASA-tolerated CSU (B), and ASA-exacerbated
T
pesults
he clinical and laboratory characteristics of the study pop-
lation are summarized in table 1. Males were slightly
ess represented in the AtCSU. As expected, patients with
eCSU had higher levels of LTE4 after challenge with ASA
han either NC or AtCSU, whereas no difference was found
or LTE4 basal levels (table 1).
he genotype frequencies in the study population accord-
ng to clinical diagnosis are shown in table 2. All the analy-
ed SNPs were in Hardy-Weinberg equilibrium in the con-
rol group. COX-1 22 C/T, COX-2 5′UTR T/G, COX-2
xon 10 T/C, and FLAP -336 G/A polymorphisms were
ignificantly associated with CSU, carriers of the minor
llele being more represented in the CSU group. Similar
esults were obtained comparing either the AtCSU or the
eCSU group with the NC group, respectively. On the other
and, no significant difference in genotype distribution was
ound between the AtCSU and AeCSU groups (table 2).
ll the SNPs that were associated with CSU at univariate
nalysis were included in a sex- and age-adjusted multiple
egression model. In that model only 3 SNPs, i.e. COX-2
′UTR T/G, COX-2 Exon 10 T/C, and FLAP -336 G/A,
emained significantly associated with CSU, as shown in
gure 1. Similar results were obtained as regards the specific
ssociation with AtCSU and AeCSU, even if the statisti-
al significance of the association of COX-2 Exon 10 T/C
olymorphism with AeCSU was marginally lost (ﬁgure 1).
oreover, in logistic regression analysis while all the 3
bove mentioned polymorphisms remained significantly
ssociated with CSU, no significant interaction among them
n predicting CSU risk was found (table 3). Such results
rompted us to develop an additive model considering the
um of effects of unfavourable, CSU-associated alleles.
hen, we evaluated the combined effects of these 3 SNPs
nd on the basis of them we constructed a genetic score,
eflecting the sum of the concomitant “unfavourable” alle-
es (i.e. the alleles associated with CSU: COX-2 5′UTR G
llele, COX-2 Exon 10 C allele, and FLAP -336 G/A allele),
heoretically ranging from 0 (no risk allele present) to 6 (all
he risk alleles present). As shown in ﬁgure 2, the proportion
f CSU patients increased progressively with the increasing
umber of unfavourable alleles (P < 0.001 by 2-test for
inear trend). Remarkably, all the subjects with more than
risk alleles had CSU and also in the group with 2 risk0
lleles, the great majority of subjects, i.e. 91.3% (21/23),
resented CSU, whereas in the group with no risk allele the
revalence of CSU diagnosis was about the 30% (37/122).
uch results were substantially confirmed for both AtCSU
nd AeCSU (data not shown).
able 3. Multiple logistic regression considering COX1 and AL
redictors of chronic spontaneous urticaria (CSU).
B
COX-2 5′UTR T/G 1.558
COX-2 Exon 10 T/C 1.615
FLAP -336 G/A 1.018
COX-2 5′UTR T/G * COX-2 Exon 10 T/C 19.158
COX-2 5′UTR T/G * FLAP -336 G/A 18.808
COX-2 Exon 10 T/C * FLAP -336 G/A 0.138CSU (C) of COX2 5′UTR G and Exon 10 C, and FLAP -336
A carriership in a multiple logistic regression, sex- and age-
adjusted and including all the SNPs which were associated
with CSU at the univariate analysis.EJD, vol. 21, n◦ 1, January-February 2011
Finally, as regards the assessment of LTE4 levels before
and after ASA challenge according to the different gene
polymorphisms, no significant difference was found for
LTE4 basal levels (data not shown). On the other hand,
OX5 gene polymorphisms and their potential interaction as
Standard error P
0.461 0.001
0.541 0.003
0.483 0.035
17.008 0.999
11.832 0.999
1.253 0.912
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Figure 2. Prevalence of subjects with chronic spontaneous
urticaria (CSU) according to a polygenic model constructed
on the basis of the following three polymorphisms, i.e. COX2
5′UTR T/G and Exon 10 T/C, and FLAP -336 G/A. The COX2
5′UTR G and Exon 10 C, and FLAP -336 A alleles are consid-
ered as risk alleles.
Table 4. Predictors of post-ASA challenge LTE4 levels vari-
ability in linear regression model.
Standardized
beta-coefﬁcient
P
Age (years) −0.005 0.823
Male sex −0.054 0.017
AtCSU −0.006 0.808
AeCSU 0.965 <0.001
COX-1 22 T carriership 0.072 0.001
A
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pCOX-2 5′UTR G carriership −0.026 0.271
djusted R2 = 0.938
OX-1 22 T carriers (52.5 ± 31.1 versus 39.1 ± 26.9
n CC homozygotes, P = 0.039 by t-test) and COX-2
′UTR G carriers (54.0 ± 26.4 versus 38.3 ± 27.9 in
T homozygotes, P = 0.011 by t-test) seemed to present
igher LTE4 levels after ASA challenge. However, in a lin-
ar regression model after adjustment for disease status,
nly COX-1 22 T carriership remained a significant pre-
ictor of post-challenge LTE4 levels variability (table 4).
further analysis showed that COX-1 22 T carriers pre-
ented particularly high LTE4 levels after ASA challenge
n the AeCSU group (77.5 ± 4.7 versus 67.2 ± 10.4 in
C homozygotes, P = 0.001 by t-test).
iscussion
rticaria is a common skin disorder, classified as acute and
hronic [13-16] Generally, in 40 to 60% of patients with
hronic urticaria, the cause of chronic urticaria cannot beJD, vol. 21, n◦ 1, January-February 2011
dentified and in such cases, urticaria is defined as CSU.
owever, with the ingestion of ASA and/or NSAIDs and/or
ood additives, hypersensitivity can aggravate urticaria in
hese patients [13-17]. The choice of therapy in these
atients, the particular subgroups of patients affected byCSU with ASA or food additive hypersensitivity, is impor-
tant, since not all respond to classic treatment (17) and
the use of antileukotrienes has been suggested [9, 10, 18,
19]. However, it has been postulated that ASA sensitivity
may be caused by an increased production of Cys-LT and a
relative inhibition of COXs [8, 20], so that there would be
a shift in the arachidonic acid metabolism away from the
cyclooxygenase (COX) pathway toward the lipo-oxygenase
(LO) pathway, which synthesized Cys-LTs (1). Our work-
ing hypothesis was that polymorphisms of these candidate
genes could affect these pathways and, consequently, the
risk of CSU and/or hypersensitivity to ASA. In the litera-
ture there are few studies that have assessed the potential
role of candidate gene polymorphisms in CSU subjects. A
previous study demonstrated that promoter polymorphisms
of 5-LO (-1708 G/A) and CYSLTR1 (-634C/T) were sig-
nificantly different between aspirin-intolerant asthma and
aspirin-induced urticaria/angioedema, suggesting different
contributions to the lipo-oxygenase pathway [21, 22].
This is the first study, to our knowledge, to investigate
the possible influence of the polymorphisms of COXs and
FLAP on CSU risk and on the levels of urinary leukotrienes,
before and after oral challenge with ASA. We analyzed
the polymorphisms of Cox-1, Cox-2, and FLAP in CSU
patients and in controls from Northern Italy. We found that
COX-2 5′UTR T/G, COX-2 Exon 10 T/C, and FLAP -336
G/A polymorphisms were associated with CSU. More pre-
cisely, a significant association was found for both AtCSU
and AeCSU, whereas no significant difference in genotype
distribution was found between AtCSU and AeCSU groups.
Such results may suggest an ASA-independent link of the
above mentioned polymorphisms with CSU.
Interestingly, we found also an additive effect of these SNPs
on CSU risk. Of note, the use of a polygenic additive model
in evaluating the combined effect of more risk alleles was
further supported by the fact that no significant interaction
among them in determining CSU risk was found. Indeed,
the proportion of CSU patients increased progressively with
increasing number of risk alleles, i.e. the alleles associ-
ated with CSU, and remarkably all the subjects with more
than 2 risk alleles had CSU in our study-population. We are
tempted to speculate that similar polygenic scores may be
useful tools in future clinical practice, but these results cer-
tainly should be further investigated and replicated before
drawing any kind of conclusion.
In addition, we evaluated the urinary LTE4 values, before
and after ASA-challenge. Unfortunately, we do not have the
data of urinary prostaglandins. COX-1 22 T carriership was
a significant predictor of post-challenge LTE4 level vari-
ability, suggesting a potential influence on the leukotriene
pathway. However, COX-1 C/T was only slightly associ-
ated with either AtCSU or AeCSU at univariate analysis
and, moreover, the statistical significance of this association
was lost after adjustment in a multiple regression model. On
the other hand, the CSU-associated COX-2 5′UTR G allele
seemed to present higher LTE4 levels after ASA challenge,
but the statistical significance of this association was lost
after adjustment in the linear regression model for urinary
LTE4 level variability. Such inconsistencies and disagree-51
ments in the results may also be related to the relatively low
number of subjects enrolled and, consequently, to a lack of
statistical power.
Certainly, the current study presents several limitations,
mainly related to the case-control design and the relatively
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dow sample size. Moreover, data about some other poten-
ial candidate polymorphisms, such as those of 5-LO, are
acking, as well as data about other markers of interme-
iate inflammatory pathways, like urinary prostaglandins.
herefore, our results should be considered only as
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